Aflac, Inc.

As of September 12, 2025, Aflac, Inc. shows a mildly bullish trend with mixed signals from MACD and moving averages, having underperformed the S&P 500 over the past year but outperformed in the 3- and 5-year periods.

As of August 5, 2025, Aflac, Inc. is considered very expensive with a high P/E ratio of 36 and other valuation metrics indicating overvaluation compared to peers like Progressive Corp. and MetLife, despite its strong long-term performance.

As of June 6, 2025, the trend is mildly bearish due to bearish weekly MACD and KST indicators, despite a bullish weekly RSI and mildly bullish signals from Dow Theory on longer time frames.

As of April 30, 2025, Aflac, Inc. is considered overvalued with a P/E ratio of 36 and a price-to-book value of 4.84, despite a 16.92% return over the past year, which exceeds the S&P 500's 10.26% return.

As of March 2022, Aflac, Inc.'s management team includes Chairman and CEO Daniel Amos, Lead Independent Director W. Paul Bowers, and Independent Directors Toshihiko Fukuzawa, Thomas Kenny, Georgette Kiser, and Karole Lloyd, who collectively guide the company's strategic direction and governance.

Aflac, Inc. is a large-cap holding company specializing in supplemental health and life insurance. As of March 2025, it has a market cap of approximately $125.61 billion and reported a net profit of $29 million.

As of Jun 18, Aflac, Inc. has a market capitalization of $125.61 billion, with net profit of $3.59 billion over the last four quarters and total assets of $117.40 billion.